Biomarin Pharmaceutical (Biomarin Pharmaceutical) Debt-to-Equity

: 0.22 (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

Biomarin Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $503 Mil. Biomarin Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $593 Mil. Biomarin Pharmaceutical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4,952 Mil. Biomarin Pharmaceutical's debt to equity for the quarter that ended in Dec. 2023 was 0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biomarin Pharmaceutical's Debt-to-Equity or its related term are showing as below:

BMRN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.22 Med: 0.27 Max: 0.42
Current: 0.22

During the past 13 years, the highest Debt-to-Equity Ratio of Biomarin Pharmaceutical was 0.42. The lowest was 0.22. And the median was 0.27.

BMRN's Debt-to-Equity is ranked worse than
58.6% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs BMRN: 0.22

Biomarin Pharmaceutical Debt-to-Equity Historical Data

The historical data trend for Biomarin Pharmaceutical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.28

0.27

0.26

0.24

0.22

Biomarin Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.24	0.24	0.23	0.22	0.22

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Debt-to-Equity falls into.

Biomarin Pharmaceutical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biomarin Pharmaceutical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(502.656	+	593.095)	/	4951.549
	=	0.22

Biomarin Pharmaceutical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(502.656	+	593.095)	/	4951.549
	=	0.22

Biomarin Pharmaceutical (NAS:BMRN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biomarin Pharmaceutical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

1BMRN:Italy BM8:Germany BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Executives

Jean Jacques Bienaime	director, officer: Chief Executive Officer	925 PAGE MILL ROAD, PALO ALTO CA 94304
George Eric Davis	officer: VP, General Counsel	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jeffrey Robert Ajer	officer: EVP, Chief Commercial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs	officer: Chief Medical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Charles Greg Guyer	officer: EVP, Chief Technical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller	officer: EVP, Chief Financial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Erin Burkhart	officer: GVP, Chief Accounting Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
V Bryan Lawlis	director
Richard A Meier	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon	director	770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612